Abstract:Abstract Phase I/II clinical studies with rapamycin analogs in breast and other cancers have demonstrated favorable responses. However, little is known on the effects of the mTOR inhibitor on breast cancer cell metastasis, which is a major cause of morbidity and death. We developed a highly sensitive 3-dimensional (3D) proliferation/invasion assay using quantitative bioluminescence (BL) imaging and applied this assay to evaluate the effects of rapamycin on the triple negative breast cancer cell line MDA-MB231. Without cytotoxicity of rapamycin on this cell line, rapamycin at 10nM inhibited the cell migration/invasion, but not at 1nM and 100nM, which was confirmed by the time-lapse single cell tracking analysis. The quantification of cytoskeleton changes showed most potent effects of 10nM rapamycin on the MDA-MB231 cells, with the formation and rearrangement of specialized cell membrane structures and actin fiber implicated in cell motility. Then, the Panorama Cell Signaling Antibody Microarray, enabling the global comparative analysis of cell signal proteins simultaneously, was exploited to analyze the effects of rapamycin on the cellular signaling network of the MDA-MB231 breast cancer cell line. 100nM rapamycin activated the MAPK pathway obviously, through the attenuated negative feedback of activated S6K1 to PI3K-Raf, which increased the expressions of activated Jun N-terminus kinase (JNK), Erk1/2, MEK-1, Raf-pS621, and MAPK-activated protein kinase 2 (MAPKAPK2) in the cells exposed to 100nM rapamycin. MEK inhibitor U0126 or PD98059 could restore the anti-migration effects of 100nM rapamycin on the MDA-MB231 cells. Furthermore, the combination of MEK inhibitors and rapamycin performed synergism on inhibiting the cell proliferation and migration/invasion. Accordingly, rapamycin at a certain dose suppresses MDA-MB231 cell migration/invasion, and the co-targeting of mTOR and MAPK pathways enhances the inhibition on cell proliferation and migration/invasion, underscoring the potential therapeutic utility of rapamycin, and rapamycin combining with MAPK inhibitors in triple negative breast cancer progression, and the results highlight the cross-talk homeostasis of mTOR and MAPK pathways in cancer treatment. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5080.

Rapamycin Inhibits Igf-1 Stimulated Cell Motility Through Pp2a Pathway

Abstract #4626: Role of Protein Phosphatase 2A in Regulation of Cell Motility

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

Rapamycin Inhibits Epithelial-to-mesenchymal Transition of Peritoneal Mesothelium Cells Through Regulation of Rho GTPases.

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.

Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.

Rapamycin Inhibiting Jurkat T Cells Viability Through Changing Mrna Expression of Serine/Threonine Protein Phosphatase 2A

Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer

Rapamycin Inhibits BAFF-stimulated Cell Proliferation and Survival by Suppressing Mtor-Mediated PP2A-Erk1/2 Signaling Pathway in Normal and Neoplastic B-lymphoid Cells.

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity

Rapamycin Inhibits B-cell Activating Factor (Baff)-Stimulated Cell Proliferation and Survival by Suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 Signaling Pathway in Normal and Neoplastic B-lymphoid Cells.

Effects Of Rapamycin On Breast Cancer Cell Migration Through The Cross-Talk Of Mapk Pathway

Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells

Rapamycin Attenuates BAFF‐extended Proliferation and Survival Via Disruption of Mtorc1/2 Signaling in Normal and Neoplastic B‐lymphoid Cells

Rapamycin inhibits proliferation and apoptosis of retinoblastoma cells through PI3K/AKT signaling pathway

Rapamycin Directly Activates Lysosomal Mucolipin TRP Channels Independent of Mtor

Antitumor Effects of Rapamycin in Pancreatic Cancer Cells by Inducing Apoptosis and Autophagy.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.